Read More Pharma Industry News Halozyme Therapeutics (HALO) completes $900m Elektrofi deal—what’s next for its royalty roadmap? Halozyme finalizes $900M Elektrofi deal to strengthen its subcutaneous biologics platform. Discover how this move impacts future royalties and delivery formats. bySrinathNovember 18, 2025